Topic Listing for Corcept Therapeutics

Access Information Accounting Changes
Acquire Other Gr-ii Antagonists Technologies Potential Products Incur Addition Other Information Report Following Factors Considered Carefully
Administration 2004 Plan Aggregated Option Exercises Values Table
Agreement Agreement Sell Purchase Securities
Agreement Sell Purchase Shares Agreement Signed Medavante Inc
Although Pivotal Phase Clinical Trial Cushings Syndrome Only Alzheimers Disease Program
Amendment Amendment Termination 2004 Plan
Amendments Annex
Annual Meeting Stockholders Anti-takeover Provisions Charter Bylaws Delaware Law Make Acquisition
Anticipated Milestones 2010 Appraisal Rights
Approval Issuance Sale Common Stock Argenta Discovery Limited
Assignment Assumptions Used Determining Fair Value Options Granted Employees
Atypical Antipsychotics Known Cause Weight Gain Audit Fees
Audit- Related Fees Tax Other Audit-related Fees Tax Other
Audits Corcept Agents Visit Premises Icon Central Supervised Authority
Authorization Sale Securities Authorization Sale Shares
Available Information Background
Background Purpose 2004 Plan Base Compensation
Basis Presentation Summary Significant Accounting Policies Believe Current Capital Sufficient Fund Operations Only Through
Beneficial Ownership Reporting Compliance Board Directors
Board Directors Recommends Vote Election Nominees Listed Above Board Meetings Committees
Brokers Fee Brokers Fees
Call 866 894-0537 Capital Stock Receivable
Cash Awards Cash Bonus
Cash Equivalents Short-term Investments Cash Equivalents Short-term Long-term Investments
Cash Sufficient Fund Through Corlux Nda Submission Cautionary Statement Regarding Forward-looking Statements
Certain Relationships Related Transactions Certificate Subsequent Sale
Certification Change Control
Change Control Arrangements Changes Interpretations Accounting Rules Regulations Such Expensing Stock
Chief Executive Officer Compensation Clinical Trials Not Demonstrate Corlux Safe Effective Program
Clinical Trials Not Demonstrate Corlux Safe Effective Treatment Clinical Trials Other Psychiatric Metabolic Disorders
Clinical Trials Other Psychiatric Neurological Disorders Closing Delivery
Code Ethics Commitments
Committed Equity Financing Facility Ceff Entered Kingsbridge 2008 Committees
Common Stock Common Stock 0001 Par Value
Common Stock Purchase Agreement Commonwealth Drive
Communications Directors Compensation Benchmarking
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Discussion Analysis Compensation Objectives
Competition Compliance Public Obligations Including Securities Laws Regulations Costly
Composition Composition Matter Patents Families Novel Selective Glucocorticoid Antagonists
Comprehensive Loss Condensed Balance Sheets
Conditions Closing Conditions Obligations Closing
Conditions Obligations Each Closing Conditions Purchasers Obligations Closing
Conflict Extent Between Provisions Laboratory Services Appendix Master Consent Independent Registered Public Accounting Firm
Contracts European Trial Activities Denominated Euros Bear Currency Contractual Obligations
Contractual Obligations Commercial Commitments Controls Procedures
Corcept Therapeutics Announces 2004 Results Corcept Therapeutics Announces 2007 Results
Corcept Therapeutics Incorporated Corlux
Corlux Approved Unable Obtain Acceptable Prices Adequate Coverage Corlux Approved Unable Obtain Acceptable Prices Adequate Reimbursement
Corlux Cushings Syndrome Corlux Future Product Candidates Conflict Patents Others Become
Corlux Other Metabolic Disorders Corlux Psychotic Depression
Corlux Psychotic Features Depression Corlux Psychotic Features Pmd
Cort 108297 Cort 108297 Demonstrated Statistically Significant Weight Control
Cort 108297 Demonstrated Statistically Significant Weight Gain Prevention Cort 108297 Prevention Reversal Antipsychotic Induced Weight Gain
Covenants Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Risks Concentrations Critical Accounting Policies Estimates
Currency Risk Current Capital Not Sufficient Fund Operations Beyond Early
Current Capital Not Sufficient Fund Operations Beyond End Current Capital Sufficient Fund Operations Only 2007 Need
Current Capital Sufficient Fund Operations Only 2008 Need Current Capital Sufficient Fund Operations Only Through 2008
Current Treatments Pmd Current Treatments Psychotic Depression
Cushings Syndrome Deferred Stock-based Compensation Employee Options
Defined Contribution Plans Definitions
Departure Directors Certain Officers Election Appointment Compensation Depend Clinical Investigators Sites Enroll Patients Trials Other
Depend Heavily Success Lead Product Corlux Still Development Description Business
Description Business Basis Presentation Determination Compensation
Development Agreements Development Plan Corlux Not Certain Require Additional Expensive
Development Stage Director Compensation
Director Nomination Director Not Standing Re-election
Directors Executive Officers Registrant Directors Not Standing Re-election
Directors Officers Liability Insurance Discovery Research
Discovery Research Intellectual Property Documents Incorporated Reference
Draw Down Terms Effect 162 Internal Revenue Code
Efforts Discover Develop Commercialize New Product Candidates Beyond Elements Executive Compensation
Eligibility Receive Awards Performance Criteria Employees
Employees Directors Entry Material Definitive Agreement
Equity Compensation Plan Information Estimates
Even Receive Approval Marketing Sale Corlux Treatment Cushings Even Receive Approval Marketing Sale Corlux Treatment Psychotic
Exact Name Corporation Specified Charter Exact Name Registrant Specified Charter
Executive Compensation Executive Compensation Base Salary
Executive Officers Exercises Net Exercise Right Pursuant Thereof Requests Certificates
Exhibits Face Competition Companies Substantial Financial Technical Marketing Resources
Fail Continue Meet Applicable Nasdaq Capital Market Requirements Fail Continue Meet Applicable Nasdaq Global Market Requirements
Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Commercializing Fair Value
Fair Value Measurements Fair Value Measurements Recurring Basis
Fast Track Designation Development Program Corlux Treatment Psychotic Federal Tax Aspects
Financial Results Financial Statements Exhibits
Financial Statements Supplementary Data Financing
Fold Detach Here Read Reverse Side Form 10-k
Form 10-q Form Draw Down Notice
Form Opinion Latham Watkins Llp Form Registration Rights Agreement
Form Warrant Former Name Address Changed Since Last Report
Forward-looking Information Forward-looking Statements
General General Compensation Philosophy
Glucocorticoid Receptor Antagonists Going Concern
Government Regulation Gr-ii Antagonist Platform
Grants Plan-based Awards Grants Plan-based Awards 2007
Grants Plan-based Awards 2008 Held 2006
Held 2007 Held 2008
Held 2009 Holder
Impairment Investments Important Immediate Attention Required
Income Taxes Incur Increased Costs Result Recently Enacted Proposed Changes
Indemnification Indemnification Directors Officers
Index Index Financial Statements
Institute Study Aging Payable Intellectual Property
Interests Certain Officers Directors Investigator Meetings Corcept Require Representative Icon Central Attend
Key Milestones 2010 Laboratory Services Appendix
Lease Obligations License Agreement
Licensed Patent Covering Mifepristone Treat Pmd Method Rather Licensed Patent Covering Mifepristone Treat Psychotic Depression Method
Liquidated Damages Share Amounts Liquidity
Liquidity Capital Resources Long-term Performance-based Equity Incentive Program
Lose Key Personnel Unable Attract Retain Additional Skilled Management
Management Plans Management Plans Regarding Liquidity
Management Weight Gain Induced Antipsychotics Managements Plans
Manufacturing Manufacturing Agreement
Manufacturing Agreements Manufacturing Capabilities Currently Depend Parties Single Source Suppliers
Market Information Market Performance Graph
Market Price Common Stock Highly Volatile Market Price Common Stock Highly Volatile Due Limited
Market Risk Master Services Agreement
Medavante Medical Education Commercialization
Miscellaneous Name Person Filing Proxy Statement Other Registrant
Need Additional Capital Failure Obtain Acceptable Terms Harm Need Additional Capital Near Future Order Complete Activities
Need Additional Capital Order Complete Development Commercialization Corlux Need Additional Capital Sooner Anticipated Reduce Ability Compete
Need Increase Size Organization Experience Difficulties Managing Growth Net Loss Per Share
Net Operating Loss Carryforwards New Chemical Entity Cort 108297
New Chemical Entity-cort 108297 New Plan Benefits
Nominees Nominees Board Directors
Non-employees Non-operating Income Net
Non-transferability Awards Nonqualified Deferred Compensation
Not Able Pursue Product Research Development Opportunities Unable Notices
Number Number 000-50679
Occurrence Catastrophic Disaster Other Similar Events Cause Damage Off-balance Sheet Arrangements
Officers Officers Certificate
Officers Directors Principal Stockholders Acting Group Able Significantly Officers Directors Principal Stockholders Acting Group Well Paperboy
Officers Directors Principal Stockholders Control Majority Common Stock Olanzapine Active Ingredient Zyprexa
Option Exercises Stock Vested Options Executive Officers
Options Granted Last Orpan Drug Designation Corlux Treatment Endogenous Cushings Syndrome
Orphan Drug Designation Corlux Treatment Endogenous Cushings Syndrome Other Accrued Liabilities
Other Elements Compensation Perquisites Other Events
Other Information Other Liabilities
Other Matters Others Identify Side Effects After Product Candidates Market
Others Identify Side Effects After Products Market Required Outlook Remainder 2009
Outstanding Equity Awards Year-end Overview
Overview Psychotic Depression Overview Psychotic Major Depression
Part Part Certain Transactions
Part Financial Information Part Other Information
Party Manufacturers Corlux Fail Comply Fda Regulations Otherwise Pension Benefits
Performance Goals Periodic Performance-based Cash Compensation Performance Graph
Performance-based Compensation Periods 2007 2006
Phase Trial Study Plan Distribution
Pmd Program Policies Respect Equity Compensation Awards
Potential Payments Termination Change Control Power Attorney
Pre-approval Audit-related Non-audit Services Preemptive Rights
Preferred Stock Prices
Principal Accountant Fees Services Principal Accounting Fees Services
Principal Effects Approval Non-approval Proposal Pro-forma Net Loss Information Required Sfas 123 Options
Pro-forma Net Loss Information Required Sfas123 Options Accounted Proceeds Sale Registered Securities
Produits Chimiques Auxiliaires Synthése Properties
Property Equipment Proposal Approval Amendment Restatement 2004 Equity Incentive Plan
Proposal Election Directors Proposal Ratification Independent Registered Public Accounting Firm
Proxy Solicited Board Directors Psychiatric Rating Services Provided Third-party Medavante Additional Screening
Psychotic Depression Psychotic Major Depression
Public Perception Active Ingredient Corlux Mifepristone 486 Limit Public Perception Active Ingredient Corlux Mifepristone Ru-486 Limit
Purchase Sale Common Stock Purchaser Registered Broker-dealer Received Common Stock Other Transaction-based
Purchasers Names Purpose
Quantitative Qualitative Disclosures Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Data Quorum Voting Requirements
Rapid Technological Change Make Product Candidates Obsolete Rapid Technological Change Make Products Obsolete
Reason Stockholder Approval Reasons Financing
Recent Highlights Recently Adopted Accounting Standards
Recently Issued Accounting Standards Recitals
Reclassification Recommendation Board Directors
Registrants Telephone Number Including Area Code Registration Procedures
Registration Rights Registration Rights Agreement
Registration Shares Compliance Securities Act Regulation Disclosure
Related Party Transactions Remainder Page Intentionally Left Blank
Remainder Page Intentionally Left Blank Signature Follows Report Audit Committee
Report Compensation Committee Report Independent Registered Public Accounting Firm
Representations Warranties Covenants Representations Warranties Covenants Investor
Representations Warranties Covenants Purchasers Required Pay Significant Amounts Not Able Meet Obligations
Required Vote Research
Research Agreements Research Development
Research Development Agreements Research Human Biology
Responsibilities Results Operations
Results Operations Financial Condition Return Promptly Enclosed Envelope
Revenue Recognition Risks Related Business
Role Cortisol Disease Sale Substantial Number Shares Common Stock Cause Price
Sale Unregistered Securities Sales Repurchases Securities
Sales Staff Limited Marketing Activities Need Develop Capabilities Sample Project Contract
Schedule 14a Securities Analysts Not Continue Provide Initiate Coverage Common
Securities Purchase Agreement Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Segment Reporting
Selective Gr-ii Antagonist Cort 108297 Prevention Weight Gain Selling Stockholder Notice Questionnaire
Service Mechanics Set Off
Severance Agreement Severance Arrangements
Severance Change Control Agreements Severance Change Control Arrangements
Shares Subject 2004 Plan Signature
Signatures Signatures Following Page
Significant Agreements Special Meeting Stockholders
Stanford License Agreements Stock
Stock Appreciation Rights Stock Awards
Stock Delisted Nasdaq Global Market Delisting Occurs Business Stock Option Plans
Stock Options Stock Options Consultants
Stock Options Other Equity Compensation Stock-based Compensation
Stock-based Compensation Arises Granting Stock Options Employees Directors Stock-based Compensation Employee Options
Stock-based Compensation Expense Related Non-employees Stock-based Compensation Options Arises Granting Stock Employees Directors
Stock-based Compensation Options Employees Impact Adopting Sfas 123r Stock-based Compensation Options Employees-impact Adopting Sfas 123r
Stockholder Notes Receivable Stockholder Proposals 2007 Annual Meeting
Stockholder Proposals 2008 Annual Meeting Stockholder Proposals 2009 Annual Meeting
Stockholder Proposals 2010 Annual Meeting Stockholders
Stockholders Record Dividends Study
Subject Fines Penalties Injunctions Determined Promoting Products Unapproved Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Substantial Exposure Product Liability Claims Not Adequate Insurance Summary
Summary 2004 Plan Summary Compensation Table
Summary Registration Rights Summary Terms Securities Purchase Agreement
Table Contents Tax Considerations
Termination Third-party Manufacturers Corlux Fail Comply Fda Regulations Otherwise
Three- Nine-month Periods 2006 2005 Top Form
Unable Obtain Acceptable Prices Adequate Reimbursement Products Third-party Unable Obtain Maintain Regulatory Approval Limited Ability Commercialize
Unable Protect Trade Secrets Proprietary Information Ability Compete Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Unregistered Sales Equity Securitiesand Proceeds
Vote Important Vote Proxy Mail
Warrant Warrants
Washington 20549 Weight Gain Associated Antipsychotic Medications
Weight Gain Caused Antipsychotics Whereas
Wwwcontinentalstockcom Year-end Option Values
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki